A new company, Metsera, has emerged in the field of health and medicine with a significant focus on obesity drug development. Backed by investment firm Population Health Partners and ARCH Venture Partners, Metsera has raised an impressive $290 million in seed and Series A financing. This funding round was led by ARCH and Population Health Partners, with support from F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2.
Metsera’s approach to building its pipeline involved a thorough search through the pipelines of 200 companies, including some overlooked pharmaceutical shelves. The company has already made strategic moves by licensing several drug candidates from South Korean biotech D&D Pharmatech, in a deal valued at over $740 million in licensing fees and milestone payments.
The team behind Population Health Partners, which includes veterans from Pfizer and The Medicines Company, brings a wealth of experience to the table. This collaboration with ARCH Venture Partners and other key investors positions Metsera as a promising player in the obesity drug development space.
With the infusion of funds and a diverse portfolio of drug candidates, Metsera is poised to make significant strides in addressing the challenges of obesity. The company’s emergence from stealth mode marks a new chapter in the quest for innovative solutions in the field of health and medicine.
